1. Home
  2. TNET vs ZYME Comparison

TNET vs ZYME Comparison

Compare TNET & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$47.58

Market Cap

1.7B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.00

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
ZYME
Founded
1988
2003
Country
United States
United States
Employees
2700
264
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
TNET
ZYME
Price
$47.58
$23.00
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$65.80
$38.90
AVG Volume (30 Days)
360.2K
610.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
33.33
EPS
1.90
N/A
Revenue
$5,010,000,000.00
$105,965,000.00
Revenue This Year
N/A
$183.10
Revenue Next Year
$3.30
N/A
P/E Ratio
$25.17
N/A
Revenue Growth
N/A
38.87
52 Week Low
$33.67
$11.86
52 Week High
$77.61
$29.75

Technical Indicators

Market Signals
Indicator
TNET
ZYME
Relative Strength Index (RSI) 63.42 36.59
Support Level $34.47 $22.28
Resistance Level $49.50 $23.66
Average True Range (ATR) 1.94 0.92
MACD 0.13 -0.15
Stochastic Oscillator 78.87 17.07

Price Performance

Historical Comparison
TNET
ZYME

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: